Onkodisruptor Electroporator



The Electroporator, designated as Onkodisruptor®, is a state of the art of the electrochemotherapy ECT and electrogenetherapy EGT apparatus which is the evolution of the electroporators successfully used by our group over the past ten years. The characteristics of the train of permeabilizing waveforms, as well as the configuration of the novel electrodes specifically developed for this equipment, make the Onkodisruptor® a unique product. Regarding the unique features of our product we state that the novel pulses are 2 times faster than the previously developed electroporation systems and cause 2 times less discomfort to the animal.

The Electroporator generates a train of 8 biphasic pulses that have been stabilized by a dedicated software program. Such pulses have an interpulse of 10 microseconds and have a 50+50 microseconds duration. The instrument voltage goes from 100 up to 1500 volts and is regulated by the operator. An acoustic signal is generated each time the apparatus successfully discharges the train of pulses and there is a safety switch that triggers an autodischarge program if the impulses are not delivered within 30 seconds.

Biopulse  is the sole source of such equipment specifically developed for Veterinary profession. Onkodisruptor® has been purchased from many specialized veterinary clinics and universities around the world.

The possibility of delivering traditional drugs and new synthetic molecules through equipment which facilitates the specific uptake by the tumor cells, will allow for a signifcant reduction of unwanted side effects, while maintaining, or even increasing, the pharmacological efficacy.

Onkodisruptor Electroporator Full Set

Electroporator Onkodisruptor® conforms EU certifications: EN 60950/55011/61000-6-1/61000-6-3

Company Updates

  • 11-15-2014 A new article was published on Journal of Equine Veterinary Science
  • 08-06-2014 A new article was published on Journal of Cell Physiology
  • 15-05-2015 The new needles are in the test phase.
  • 10-06-2016 Check out the new publications page.
  • 13-06-2016 New Blog post about one recent Onkodisruptor application.
  • 20-12-2016 New Blog post about one recent Onkodisruptor application : Salvage electrochemotherapy in a stallion with recurring penile fibrosarcoma
  • 03-02-2017 New Blog post about one recent Onkodisruptor application :Surgery and electrochemotherapy treatment of incompletely excised mammary carcinoma.
  • 08-03-2017 New Blog post about one recent Onkodisruptor application :Ultrasound guided electrochemotherapy for the treatment of a c-lear cell thymoma in a cat
  • 31-07-2017 New article about : Treatment of an advanced squamous cell carcinoma of the hoof in a mare.
  • 10-08-2017 First Onkodisruptor study on Humans (blog article here)  : Succesful treatment of plantar warts with intralesional bleomicin and electroporation: Pilot prospective study.

Biopulse will be present at these conferences :

  • WORKSHOP ELECTROCHEMOTHERAPY BRASIL I Workshop on Electrochemotherapy, Ribeirão Preto- SP. NOVEMBER 9-10 2016 University of Franca (UNIFRAN).With Dr. Enrico Pierluigi Spugnini.
  • DUBAI MED LAB 2017 6-9 Feb 2017. We will be guests at the stand of DAS italy – Hall Z6 number C59. Article.
  • Dr Spugnini will be present as Speaker at the European Society of Veterinary Oncology Annual Congress in Lyon .From 20th to 22nd April 2017.

Electroporation News

Treatment of an advanced squamous cell carcinoma of the hoof in a mare

A new scientific paper of our research team directed by Dr. Enrico Pierluigi Spugnini and Prof. Alfonso Baldi has been published : Isolated limb perfusion electrochemotherapy for the treatment of an advanced squamous cell carcinoma of the hoof in a mare. We thank for the valuable contribution and help of all the staff members of the Equivet clinic in Rome directed by Dr Carlo Bolaffio and

Succesful treatment of plantar warts with intralesional bleomicin and electroporation: Pilot prospective study.

Onkodisruptor Electroporator : A pilot prospective study on Humans. This article report on the data produced in the first human trial performed with our apparatus Onkodisruptor ©. The clinical study registered with EUDRACT N° 2014-003339-21 was performed under the direction of dr. Paola Pasquali  from the Dermatology Service, Pius Hospital De Valls, Tarragona, Spain, in collaboration with prof. Salvador Gonzalez

Why Choose Us

  • Our equipments are manufactured with the highest quality standards.

  • We assist our clients step by step providing technical and scientific support 24h/7d.

  • Our customers have a very high satisfaction rate and a short ROI.
  • We support ethical treatment of animals and our studies are completely cruelty free.
  • Electroporator Onkodisruptor® is unique and there are no other electroporators on the market with the same characteristics and Scientific Results.

  • Our partner and and manufacturer DAS is a certified company UNIEN ISO 9001 and UNIEN ISO 13485.

Electroporator Quality Standards

Beware of imitations, many products on the market as well as not producing any scientific and clinical outcome can be dangerous for patients and operators.

Onkodisruptor is the undisputed leader in the veterinary field with a vast scientific production and an unrivaled customer satisfaction.

Our Clients and Friends